SML1075
Atglistatin
≥98% (HPLC), powder, adipose triglyceride lipase inhibitor
동의어(들):
3-(4′-(Dimethylamino)-[1,1′-biphenyl]-3-yl)-1,1-dimethylurea
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C17H21N3O
CAS 번호:
Molecular Weight:
283.37
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
제품 이름
Atglistatin, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
SMILES string
CN(C)C(NC1=CC=CC(C2=CC=C(N(C)C)C=C2)=C1)=O
InChI
1S/C17H21N3O/c1-19(2)16-10-8-13(9-11-16)14-6-5-7-15(12-14)18-17(21)20(3)4/h5-12H,1-4H3,(H,18,21)
InChI key
AWOPBSAJHCUSAS-UHFFFAOYSA-N
Application
Atglistatin has been used as a selective inhibitor of adipose triglyceride lipase (ATGL).
Biochem/physiol Actions
Atglistatin is a selective inhibitor of adipose triglyceride lipase (ATGL).
Atglistatin is the first selective inhibitor of adipose triglyceride lipase (ATGL), the rate limiting enzyme involved in the mobilization of fatty acids from cellular triglyceride stores. Atglistatin has an IC50 of 0.7 μM in E.coli and no activity against monoglycerol lipase (MGL), hormone-sensitive lipase (HSL), or pancreatic lipase and lipoprotein lipase PNPLA6 and PNPLA7. ATGL generates diacylglycerol from cellular triglyceride stores, which is then degraded by hormone-sensitive lipase (HSL) and monoglyceride lipase into glycerol and fatty acids, promoting the synthesis of lipotoxic metabolites that have been associated with the development of insulin resistance. Atglistatin inhibition of ATGL has been shown to reduce fatty acid mobilization in vitro and in vivo.
Other Notes
Produced under the license of University of Graz/Graz University of Technolog
Still not finding the right product?
Explore all of our products under Atglistatin
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
문서
Discover Bioactive Small Molecules for Lipid Signaling Research
지질 신호전달 연구를 위한 생체 활성 저분자